Corrigendum to Incorporating New Approach Methodologies into Regulatory Nonclinical Pharmaceutical Safety Assessment

Jan Turner[1], Pandora Pound[1], Carla Owen[2], Isobel Hutchinson[2], Marina Hop[3], David Y. S. Chau[4], Lady V. Barrios Silva[4], Mike Coleman[5], Audrey Dubourg[6], Lorna W. Harries[7], Victoria Hutter[8], J. Gerry Kenna[1], Volker M. Lauschke[9], Winfried Neuhaus[10], Clive Roper[11], Paul B. Watkins[12], Jonathan Welch[13], Laura Rego Alvarez[14] and Katy Taylor[14]

[1]Safer Medicines Trust, Kingsbridge, UK; [2]Animal Free Research UK, London, UK; [3]Viveo Consulting Ltd., London, UK; [4]Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, London, UK; [5]College of Health and Life Sciences, Aston University, Birmingham, UK; [6]CN Bio Innovations Limited, Cambridge, UK; [7]University of Exeter Medical School, Exeter, UK; [8]ImmuONE Limited, Hatfield, UK; Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, Hatfield, UK; [9]Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany; [10]Austrian Institute of Technology GmbH, Competence Unit Molecular Diagnostics, Vienna, Austria; Department of Medicine, Danube Private University, Krems, Austria; [11]Roper Toxicology Consulting Limited, Edinburgh, UK; [12]Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School Of Pharmacy, Chapel Hill, NC, USA; [13]Newcells Biotech, Newcastle upon Tyne, UK; [14]Cruelty Free International, London, UK

In this Workshop Report, which appeared in *ALTEX 40*, 519-532 (doi:10.14573/altex.2212081), there were errors in Figures 2 and 3. The corrected Figures are below.



Fig. 2: Central nervous system map

Participants highlighted key functional processes (purple boxes) identified by regulators and the assay outcomes (yellow boxes) that could address those processes. Assay outputs, using the NAM platforms (blue boxes), cell types (orange boxes), and measurements (green boxes), are integrated to provide evidence of the compound-related effect on each system. Boxes with dotted lines indicate current/new developments in progress or required.

2D, 2-dimensional; 3D, 3-dimensional; A/B and B/A, "A-to-B" direction and "B-to-A" direction; ATP, adenosine triphosphate; BBB, blood-brain barrier; CNS, central nervous system; hCMEC, human cardiac microvascular endothelial cells; hiPSC, human induced pluripotent stem cells; LDH, lactate dehydrogenase; MEA, microelectrode/multielectrode array; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT, 3:(4,5:dimethylthiazol:2:yl):2,5:diphenyltetrazolium bromide; TEER, trans-epithelial/transendothelial electrical resistance; XTT, (2,3:bis:(2:methoxy:4:nitro:5:sulfophenyl):2H:tetrazolium:5:carboxanilide

doi:10.14573/altex.2408291



Fig. 3: Cardiovascular map

Participants highlighted key functional processes (purple boxes) identified by regulators and the assays that could address those processes. Assay outputs, using the NAM platforms (blue boxes), cell types (orange boxes), and measurements (green boxes), are integrated to provide evidence of the compound-related effect on each system.

2D, 2-dimensional; 3D, 3-dimensional; ADME, absorption, distribution, metabolism and excretion; APD, action potential duration; CHO, Chinese hamster ovary; FDSS, functional drug screening system; FLIPR, fluorescent imaging plate reader; HEK, human embryonic kidney; hERG, human ether-à-go-go-related gene; iPSC, induced pluripotent stem cells; OOC, organ-on-a-chip; PECAM1, platelet and endothelial cell adhesion molecule 1; PBPK, physiologically based pharmacokinetic; SIRPA, signal regulatory protein alpha; TdP, torsades de pointes